Position in RPRX
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$10,466,698
+$2,032,518 QoQ
Shares Held
186,672
+6.2% QoQ
Ownership
0.032%
of shares outstanding
% of Portfolio
0.31%
of 13F equity value
Holder Rank
#150
of 646 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Moran Wealth Management, LLC holds $37,590,704 across 10 Biotechnology names. RPRX ranks #1 (27.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
This page
|
186,672 | $10,466,698 | |
| 2 | EXEL |
Exelixis, Inc.
|
141,150 | $7,679,970 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
80,381 | $6,291,420 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
19,790 | $6,255,420 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,300 | $2,681,221 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
35,374 | $1,929,297 | |
| 7 | STOK |
Stoke Therapeutics, Inc.
|
47,977 | $1,569,807 | |
| 8 | RNA |
Atrium Therapeutics, Inc.
|
33,320 | $448,154 |
All Filings in RPRX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,466,698 | 186,672 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $8,434,180 | 175,822 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $5,301,136 | 137,193 | Shares | Defined | 2026-01-26 | |
| 2025-09-30 | $4,013,593 | 113,764 | Shares | Sole | 2025-10-23 | |
| 2025-06-30 | $3,045,723 | 84,533 | Shares | Sole | 2025-07-28 | |
| 2025-03-31 | $2,770,289 | 88,991 | Shares | Sole | 2025-04-23 | |
| No filing history on record for this holder in this stock. | ||||||